hydroxyurea has been researched along with Breast Cancer in 43 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities." | 5.51 | Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. ( Gao, X; Ji, J; Li, M; Lv, J; Mao, W; Sun, C; Wang, J; Yang, W; Zhang, L; Zhao, Z, 2019) |
| "Multiple breast cancer cell models were employed to investigate whether the safe concentration of 0." | 5.46 | Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway. ( Cai, Z; Feng, Z; Guo, G; Liu, G; Luo, Y; Powell, S; Tian, Y; Tian, Z; Wang, H; Wang, S; Wang, X; Zhang, F, 2017) |
| "Paclitaxel (PTX) is a widely used chemotherapy agent and may cause cell death by apoptosis subsequent to microtubule (MT) disruption." | 5.34 | Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. ( Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J, 2007) |
| "In this study 26 women with metastatic breast cancer responding to lower dose combination chemotherapy were treated with 18 g/m2 of hydroxyurea added to the widely used combination of cyclophosphamide (CY) 6 g/m2 and thiotepa 600 mg/m2." | 5.29 | High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. ( Edwards, B; Kessinger, A; Reed, EC; Vaughan, WP, 1994) |
| " We demonstrated that lower dose of 2-hexyl-4-pentynoic acid (HPTA; 15 μM) has similar effects as 500 μM VPA in inhibiting breast cancer cell growth and sensitizing the tumor cells to hydroxyurea on MCF7 cells, EUFA423 cells, MCF7 cells with defective RPA2-p gene and primary culture cells derived from tissue-transformed breast tumor cells." | 3.96 | 2-hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair. ( Cai, Z; Ding, W; Feng, Z; Lim, D; Liu, G; Wang, Z; Zhang, F, 2020) |
| "The time course of DNA repair, using (3H)thymidine uptake as parameter, was measured during 8 h after a single exposure to 2, 8, and 16 UV-C J/m2 in lymphocytes of 8 cancer patients, 1 xeroderma pigmentosum patient and 10 controls." | 3.68 | Differences in the kinetics of DNA repair in cancer patients and healthy controls. ( Kovacs, E; Langemann, H, 1991) |
| "Hydroxyurea is an S-phase specific drug." | 2.67 | Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial. ( Blumenreich, MS; Gentile, PS; Hamm, JT; Joseph, UG; Kellihan, MJ; Lalley, KA; Seeger, J; Sherrill, EJ; Sheth, SP; Sullivan, DM, 1993) |
| "Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin." | 2.67 | Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994) |
| "TCGA analyses of human breast cancers revealed that NS is co-enriched positively with HR repair proteins and that high NS expression correlates with low HR defects and predicts poor progression-free survival and resistance to knockdown of cell-cycle checkpoint genes in triple-negative/basal-like breast cancers." | 1.51 | Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. ( Bhupal, PK; Ku, YH; Lin, SY; Lin, T; Lin, TC; McGrail, DJ; Meng, L; Peng, G; Tsai, RYL; Zhang, W, 2019) |
| "Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities." | 1.51 | Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. ( Gao, X; Ji, J; Li, M; Lv, J; Mao, W; Sun, C; Wang, J; Yang, W; Zhang, L; Zhao, Z, 2019) |
| "We describe a rare case of secondary breast carcinoma after chronic myeloid leukemia (CML) in a 56-year-old woman." | 1.46 | Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy. ( Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M, 2017) |
| "Multiple breast cancer cell models were employed to investigate whether the safe concentration of 0." | 1.46 | Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway. ( Cai, Z; Feng, Z; Guo, G; Liu, G; Luo, Y; Powell, S; Tian, Y; Tian, Z; Wang, H; Wang, S; Wang, X; Zhang, F, 2017) |
| "In this study, MCF-7 breast cancer cell lines harboring abrogated p53 function (vMCF-7DNp53) were employed to investigate the relationship between induction of genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A oncogenic signalings and development of centrosome amplification." | 1.39 | Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. ( Billadeau, D; D'Assoro, AB; Galanis, E; Ingle, J; Leontovich, AA; McCubrey, J; Salisbury, JL; Tallarita, T; Veroux, M, 2013) |
| "Paclitaxel (PTX) is a widely used chemotherapy agent and may cause cell death by apoptosis subsequent to microtubule (MT) disruption." | 1.34 | Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. ( Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J, 2007) |
| "In this study, breast cancer cell lines with different p53 backgrounds were used to investigate the relationship between genotoxic stress, G(1)/S cell cycle checkpoint integrity, and the development of centrosome amplification." | 1.32 | Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. ( Almodovar-Mercado, GJ; Busby, R; D'Assoro, AB; Delva, E; Farrugia, DJ; Folk, C; Johnson, H; Salisbury, JL; Stivala, F; Suino, K; Vasile, V, 2004) |
| " We found that DFMO administration to MCF-10A cells increased EGF-R mRNA and protein levels in a dose-response fashion, while HER-2neu expression was not affected." | 1.31 | Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. ( Demers, L; Manni, A; Mauger, D; Trout, D; Verderame, MF; Washington, S, 2001) |
| "Paclitaxel is a naturally occurring antimitotic agent that has been shown to stabilize microtubules, induce mitotic arrest, and ultimately induce apoptotic cell death." | 1.30 | Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. ( Fan, W; Johnson, KR; Young, KK, 1999) |
| "In this study 26 women with metastatic breast cancer responding to lower dose combination chemotherapy were treated with 18 g/m2 of hydroxyurea added to the widely used combination of cyclophosphamide (CY) 6 g/m2 and thiotepa 600 mg/m2." | 1.29 | High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. ( Edwards, B; Kessinger, A; Reed, EC; Vaughan, WP, 1994) |
| "Hydroxyurea is an antineoplastic drug with a broad spectrum of clinical activity and minimal nonhematopoietic toxicity." | 1.28 | High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent. ( Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (20.93) | 18.7374 |
| 1990's | 12 (27.91) | 18.2507 |
| 2000's | 9 (20.93) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Gener, P | 1 |
| Montero, S | 1 |
| Xandri-Monje, H | 1 |
| Díaz-Riascos, ZV | 1 |
| Rafael, D | 1 |
| Andrade, F | 1 |
| Martínez-Trucharte, F | 1 |
| González, P | 1 |
| Seras-Franzoso, J | 1 |
| Manzano, A | 1 |
| Arango, D | 1 |
| Sayós, J | 1 |
| Abasolo, I | 1 |
| Schwartz, S | 1 |
| Ding, W | 1 |
| Lim, D | 1 |
| Wang, Z | 1 |
| Cai, Z | 2 |
| Liu, G | 2 |
| Zhang, F | 2 |
| Feng, Z | 2 |
| Harris, C | 1 |
| Savas, J | 1 |
| Ray, S | 1 |
| Shanle, EK | 1 |
| Pan, L | 1 |
| Duan, J | 1 |
| Qiao, W | 1 |
| Bi, L | 1 |
| Wu, D | 2 |
| Fan, Z | 1 |
| Yang, M | 1 |
| Tian, Y | 1 |
| Wang, H | 1 |
| Tian, Z | 1 |
| Luo, Y | 1 |
| Wang, S | 1 |
| Guo, G | 1 |
| Wang, X | 1 |
| Powell, S | 1 |
| Shallis, RM | 1 |
| Xu, ML | 1 |
| Curtis, SA | 1 |
| Medoff, E | 1 |
| Mixon, R | 1 |
| Folkers, A | 1 |
| Zeidan, AM | 1 |
| Lin, T | 1 |
| Lin, TC | 1 |
| McGrail, DJ | 1 |
| Bhupal, PK | 1 |
| Ku, YH | 1 |
| Zhang, W | 1 |
| Meng, L | 1 |
| Lin, SY | 1 |
| Peng, G | 1 |
| Tsai, RYL | 1 |
| Gao, X | 1 |
| Wang, J | 2 |
| Li, M | 1 |
| Lv, J | 1 |
| Zhang, L | 1 |
| Sun, C | 1 |
| Ji, J | 1 |
| Yang, W | 1 |
| Zhao, Z | 1 |
| Mao, W | 1 |
| Leontovich, AA | 1 |
| Salisbury, JL | 2 |
| Veroux, M | 1 |
| Tallarita, T | 1 |
| Billadeau, D | 1 |
| McCubrey, J | 1 |
| Ingle, J | 1 |
| Galanis, E | 1 |
| D'Assoro, AB | 2 |
| Lasho, TL | 1 |
| Mims, A | 1 |
| Elliott, MA | 1 |
| Finke, C | 1 |
| Pardanani, A | 1 |
| Tefferi, A | 1 |
| Chiker, S | 1 |
| Pennaneach, V | 1 |
| Loew, D | 1 |
| Dingli, F | 1 |
| Biard, D | 1 |
| Cordelières, FP | 1 |
| Gemble, S | 1 |
| Vacher, S | 1 |
| Bieche, I | 1 |
| Hall, J | 1 |
| Fernet, M | 1 |
| Yilmaz, B | 1 |
| Teksoz, S | 1 |
| Kilcar, AY | 1 |
| Ucar, E | 1 |
| Ichedef, C | 1 |
| Medine, EI | 1 |
| Ari, K | 1 |
| Mijatovic, T | 1 |
| Jungwirth, U | 1 |
| Heffeter, P | 1 |
| Hoda, MA | 1 |
| Dornetshuber, R | 1 |
| Kiss, R | 1 |
| Berger, W | 1 |
| Maurer, M | 1 |
| Komina, O | 1 |
| Wesierska-Gadek, J | 1 |
| Chandramouly, G | 1 |
| Willis, NA | 1 |
| Scully, R | 2 |
| SEARS, ME | 1 |
| Lomonosov, M | 1 |
| Anand, S | 1 |
| Sangrithi, M | 1 |
| Davies, R | 1 |
| Venkitaraman, AR | 1 |
| Busby, R | 1 |
| Suino, K | 1 |
| Delva, E | 1 |
| Almodovar-Mercado, GJ | 1 |
| Johnson, H | 1 |
| Folk, C | 1 |
| Farrugia, DJ | 1 |
| Vasile, V | 1 |
| Stivala, F | 1 |
| Ko, MJ | 1 |
| Murata, K | 1 |
| Hwang, DS | 1 |
| Parvin, JD | 1 |
| Chen, B | 1 |
| Parihar, K | 1 |
| He, L | 1 |
| Fan, C | 1 |
| Zhang, J | 1 |
| Liu, L | 1 |
| Gillis, A | 1 |
| Bruce, A | 1 |
| Kapoor, A | 1 |
| Tang, D | 1 |
| Henley, D | 1 |
| Isbill, M | 1 |
| Fernando, R | 1 |
| Foster, JS | 1 |
| Wimalasena, J | 1 |
| Blumenreich, MS | 1 |
| Kellihan, MJ | 1 |
| Joseph, UG | 1 |
| Lalley, KA | 1 |
| Sherrill, EJ | 1 |
| Sullivan, DM | 1 |
| Hamm, JT | 1 |
| Gentile, PS | 1 |
| Sheth, SP | 1 |
| Seeger, J | 1 |
| Vaughan, WP | 2 |
| Reed, EC | 2 |
| Edwards, B | 1 |
| Kessinger, A | 2 |
| Raschko, JW | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Newman, E | 1 |
| Somlo, G | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Kaba, SE | 1 |
| Kyritsis, AP | 1 |
| Hess, K | 1 |
| Yung, WK | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 1 |
| Levin, VA | 1 |
| Chen, J | 2 |
| Ochs, RL | 1 |
| Keegan, K | 1 |
| Hoekstra, M | 1 |
| Feunteun, J | 1 |
| Livingston, DM | 1 |
| Martin, FL | 1 |
| Cole, KJ | 1 |
| Weaver, G | 1 |
| Grover, PL | 1 |
| Phillips, DH | 1 |
| Johnson, KR | 1 |
| Young, KK | 1 |
| Fan, W | 1 |
| Manni, A | 1 |
| Trout, D | 1 |
| Verderame, MF | 1 |
| Washington, S | 1 |
| Mauger, D | 1 |
| Demers, L | 1 |
| Bierman, PJ | 1 |
| Glenn, LD | 1 |
| Armitage, JO | 1 |
| Vokes, EE | 1 |
| Moormeier, JA | 1 |
| Ratain, MJ | 1 |
| Egorin, MJ | 1 |
| Haraf, DJ | 1 |
| Mick, R | 1 |
| Weichselbaum, RR | 1 |
| Kovacs, E | 3 |
| Langemann, H | 1 |
| Bhalla, K | 1 |
| Birkhofer, M | 1 |
| Bhalla, M | 1 |
| Lutzky, J | 1 |
| Hindenburg, A | 1 |
| Cole, J | 1 |
| Ince, C | 1 |
| Almendral, A | 1 |
| Stucki, D | 1 |
| Weber, W | 1 |
| Müller, H | 1 |
| Carter, SK | 2 |
| Watne, AL | 1 |
| Covey, TH | 1 |
| Ariel, IM | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Connors, TA | 1 |
3 reviews available for hydroxyurea and Breast Cancer
| Article | Year |
|---|---|
Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; Azacitidine; Blood | 2018 |
Single and combination nonhormonal chemotherapy in breast cancer.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bre | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
6 trials available for hydroxyurea and Breast Cancer
| Article | Year |
|---|---|
Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Adenoid Cystic; Colorectal Neoplasms; Drug Administration | 1993 |
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1994 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Digestive System Neoplasms; | 1991 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
34 other studies available for hydroxyurea and Breast Cancer
| Article | Year |
|---|---|
Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells.
Topics: Animals; Breast Neoplasms; Female; Humans; Hydroxyurea; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, S | 2020 |
2-hexyl-4-pentynoic acid, a potential therapeutic for breast carcinoma by influencing RPA2 hyperphosphorylation-mediated DNA repair.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; DNA Breaks, Doub | 2020 |
Yeast-based screening of cancer mutations in the DNA damage response protein Mre11 demonstrates importance of conserved capping domain residues.
Topics: Adenocarcinoma; Breast Neoplasms; DNA Damage; DNA Repair; Early Detection of Cancer; Endodeoxyribonu | 2021 |
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Car | 2017 |
Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA; DNA Breaks, Double-S | 2017 |
Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression.
Topics: Animals; Breast Neoplasms; Carrier Proteins; Disease-Free Survival; DNA Damage; Female; Gene Express | 2019 |
Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Camptothecin; Cell Cycle Checkpoints; Cell Line, | 2019 |
Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells.
Topics: Aurora Kinase A; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Centrosome; Chromosomal Instability | 2013 |
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Combined Modality Therapy; Drug Res | 2014 |
Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 5; DNA Damage; DNA Replication; Female; | 2015 |
In Vitro/In Vivo Evaluation of Radiolabeled [(99m)Tc(CO)3](+)-Hydroxyurea and Fluorescein Isothiocyanate-Hydroxyurea.
Topics: Animals; Breast Neoplasms; Dextrans; Enzyme Inhibitors; Female; Fluorescein-5-isothiocyanate; Hydrox | 2016 |
The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2009 |
Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cell Proliferation; Cell Surviva | 2009 |
A protective role for BRCA2 at stalled replication forks.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; DNA Replication; Female; Genomic Instability; Homolo | 2011 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CANCER OF THE BREAST.
Topics: Anemia; Anemia, Myelophthisic; Antineoplastic Agents; Breast Neoplasms; Drug Therapy; Erythema; Estr | 1964 |
Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein.
Topics: Animals; BRCA2 Protein; Breast Neoplasms; Cell Cycle; Cells, Cultured; Checkpoint Kinase 2; Disease | 2003 |
Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Centrosome; Cyclin-Dependent Kinases; Female; H | 2004 |
Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle.
Topics: Adenocarcinoma; BRCA1 Protein; Breast Neoplasms; Cell Division; Cells, Cultured; Centrioles; Centros | 2006 |
ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function.
Topics: 3T3 Cells; Animals; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle Proteins; C | 2006 |
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breas | 2007 |
High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1994 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.
Topics: Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Cycle Prot | 1997 |
Genotoxicity of human milk extracts and detection of DNA damage in exfoliated cells recovered from breast milk.
Topics: Breast; Breast Neoplasms; Cells, Cultured; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; | 1999 |
Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; | 1999 |
Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage.
Topics: Androstadienes; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; Breast | 2000 |
Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line; Dose-Resp | 2001 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta | 1992 |
Differences in the kinetics of DNA repair in cancer patients and healthy controls.
Topics: Anemia, Aplastic; Breast Neoplasms; DNA Repair; Female; Humans; Hydroxyurea; In Vitro Techniques; Ki | 1991 |
Reduced DNA repair synthesis in healthy women having first degree relatives with breast cancer.
Topics: Adult; Aged; Breast Neoplasms; DNA Repair; Female; Humans; Hydroxyurea; Menopause; Middle Aged; Risk | 1987 |
Impaired DNA-repair synthesis in lymphocytes of breast cancer patients.
Topics: Adult; Aged; Breast Neoplasms; DNA; DNA Repair; Female; Humans; Hydroxyurea; Lymphocytes; Middle Age | 1986 |
Hormones, chemotherapy, and the breast cancer patient.
Topics: Administration, Oral; Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluoro | 1972 |
Anticancer therapy with hydrea: comparative study of daily vs. intermittent oral dosage.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Dr | 1974 |
An outline of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Asparaginase; Breast Neoplasms; | 1971 |